vimarsana.com
Home
Live Updates
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases ...
Related Keywords
United States ,
South San Francisco ,
California ,
San Diego ,
Pratik Multani ,
Jacobm Chacko ,
Dominic Piscitelli ,
Securities Exchange ,
European Society Of Medical Oncology ,
Linkedin ,
Nasdaq ,
Exchange Commission ,
Pharmaceuticals Inc ,
Globenewswire Inc ,
Medical Oncology ,
Escalation Data ,
Pharmacokinetic Analysis ,
Overcoming Resistance ,
San Francisco ,
Securities Act ,
Securities Exchange Act ,
Chief Financial ,
Markets ,